COPD Therapeutics Market

How Combination Therapy is Impacting the COPD Therapeutics Market Outlook: Explore Opportunities with FMI

COPD Therapeutics Market by Component, End User & Region - Forecast 2022 - 2032

COPD Therapeutics Market Outlook (2022-2032)

[342 Pages Report] The global COPD therapeutics market garnered a market value of US$ 11,668.8 Million in 2022 and is expected to accumulate a market value of US$ 20,127.7 Million by 2032, registering a CAGR of 5.1% over the forecast period.

Growth of the COPD therapeutics market can be attributed to increase in smoking and genetic disorders. The market for COPD therapeutics registered a CAGR of 4.8% during the historical period 2016-2021.

Report Attribute	Details
Estimated Base Year Value (2021)	US$ 11,053.28 Million
Expected Market Value (2022)	US$ 11,668.8 Million
Anticipated Forecast Value (2032)	US$ 20,127.7 Million
Projected Growth Rate (2022-2032)	5.1% CAGR

Surgery is recommended in case of the extreme severity of COPD, including lung volume reduction surgery, lung transplant and bullectomy, and the adoption of COPD therapeutics rises as COPD is one of the leading causes of death worldwide.

Triple therapy, LABA-ICS, LAMA-ICS, and other combination medications are examples of combination therapy. As using a bronchodilator and a corticosteroid separately is less effective, combination therapy is becoming more popular, positively impacting the market outlook.

Combination therapy is superior to monotherapy for treating the signs and symptoms of chronic obstructive pulmonary disease and enhancing the quality of life. Moreover, the COPD therapeutics market growth is anticipated to rise as a result of a rise in the number of patients who are successfully treated with combination therapy but did not improve after receiving bronchodilators or corticosteroids.

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

Which Are Some Prominent Drivers Of COPD Therapeutics Market?

Lifestyle change is responsible for increasing the habits like smoking and increase in the number of genetic disorders, which in turn are responsible for raising the number of COPD patients, and expanding the COPD therapeutics market size.

Other factors that can boost the revenue from the COPD therapeutics market are rising healthcare expenditures, leading to the adoption of COPD treatments in emerging economies. The demand for COPD therapeutics can also be owed to an increase in the level of awareness which has also led to the early diagnosis of COPD so that people can go for the treatment of the disease.

Additionally, it is projected that new product launches and advances in the global market for Chronic Obstructive Pulmonary therapeutics in respiratory illness therapy will aid in the industry's expansion. Betterment of the healthcare infrastructure in the Asia Pacific and the Middle East, and Africa is also responsible for the revenue growth of the COPD therapeutics market during the forecast period.

What Are The Challenges Faced By The COPD Therapeutics Market?

Factors that can limit the growth of the therapeutic enzymes over the forecast period include the fact that not all patients suffering from COPD are aware of the fact that they are suffering from the disease and therefore do not go for the treatment of the disease.

Also, sometimes people get to know about their disease when only medication and therapies and surgery can’t cure the disease becomes mandatory. This factor can also lead to sluggish growth in the revenue from the COPD therapeutics market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How Is The Prevalence Of COPD Escalating Demand For COPD Therapeutics In North America?

According to National Heart, Lung and Blood Institute, more than 15 million people are affected by COPD. This has increased the dependency on COPD therapeutics to access early treatment for the same. In addition, the strong presence of key players in the region is accelerating the growth of the COPD therapeutics market.

Moreover, developing health infrastructure is fuelling the growth of the COPD therapeutics market. Thus, due to the aforementioned reasons, North America is expected to possess a 36.0% market share for COPD therapeutics in 2022.

How are Government Initiatives Augmenting Demand for COPD Therapeutics in Europe?

According to Asthma Lung UK+, more than 1.3 million people suffer from COPD. This has led the country's government to design initiatives to create awareness regarding COPD. In addition, the increasing geriatric population in the country is contributing to the growth of the COPD market.

Furthermore, the growing inclination towards early treatment positively influences the market's growth. Thus, due to the reasons mentioned above, Europe is expected to hold a 30% COPD therapeutics market share in 2022.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

What Are A Few Key Start-Ups In The COPD Therapeutics Market?

Key start-up players in the COPD therapeutics market are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat, and ReAlta Life Sciences.

ReAlta Life Sciences, a key start-up in the COPD therapeutics market develops engineered peptides to harness the power of the immune system. In addition, the drug also works for COVID-19 patients.
Spirosure, a US based start-up, raised US$ 32 million funding, aimed at making the lives of people with respiratory disorders like COPD, asthma, cystic fibrosis, and pulmonary hypertension better by developing breath-based diagnostic and monitoring tools.

What Strong Is The Competition In The COPD Therapeutics Market?

The COPD market is consolidated, with only a few significant firms present, and the primary strategies used by the top companies are product portfolio expansion and mergers and acquisitions.

One of the major recent developments in the COPD therapeutics market is when AstraZeneca’s Bevespi Aerospherehas received approval in China as a maintenance treatment to relieve symptoms in patients suffering from COPD.

Key players

Pfizer Inc.
Adamis Laboratories Inc.
GlaxoSmithKline plc.
AstraZeneca
Merk & Co.
Novartis AG
Mylan N.V.
Teva Pharmaceutical Industries

Report Scope

Report Attribute	Details
Market Value in 2022	US$ 11,668.8 Million
Market Value in 2032	US$ 20,127.7 Million
Growth Rate	CAGR of 5.1% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2016-2021
Forecast Period	2022-2032
Quantitative Units	Revenue in US$ Million and CAGR from 2022-2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Component End User Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa
Key Countries Profiled	U.S Canada Brazil Mexico Germany U.K France Spain Italy Nordics BENELUX Australia & New Zealand China Japan South Korea India ASEAN GCC South Africa
Key Companies Profiled	Pfizer Inc. Adamis Laboratories Inc. GlaxoSmithKline plc AstraZeneca Merk & Co Novartis AG Mylan N.V. Teva Pharmaceutical Industries
Customization	Available Upon Request

Key Segments Profiled In The COPD Therapeutics Industry Survey

COPD Therapeutics Market by Component:

COPD Therapeutics Drug Class
Bronchodilators
Steroids
Phosphodiesterase-4 inhibitors
Theophylline
Antibiotics
COPD Therapeutics Delivery Systems
Oral
Inhalation

COPD Therapeutics Market by End User:

COPD Therapeutics across Hospitals
COPD Therapeutics across Private Clinics
COPD Therapeutics across Outpatient Departments

COPD Therapeutics Market by Region:

North America COPD Therapeutics Market
Latin America COPD Therapeutics Market
Europe COPD Therapeutics Market
Asia Pacific COPD Therapeutics Market
Middle East & Africa COPD Therapeutics Market

Frequently Asked Questions

What is the Growth Outlook for the COPD Therapeutics Market?

The global COPD therapeutics market is likely to advance at 5.1% CAGR (2022-2032).

Which Region Holds a Major COPD Therapeutics Market Share?

North America is projected to lead the COPD therapeutics market with a share of 36.0% in 2022.

What is the Future of the COPD Therapeutics Market?

COPD therapeutics market is anticipated to account for US$ 20,127.7 million by 2032.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global COPD Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Component

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Mn) Analysis By Component, 2017-2021

5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Component, 2022-2032

5.3.1. Drug Class

5.3.1.1. Bronchodilators

5.3.1.2. Steroids

5.3.1.3. Phosphodiesterase-4 inhibitors

5.3.1.4. Theophylline

5.3.2. Antibiotics

5.3.3. Delivery Systems

5.3.3.1. Oral

5.3.3.2. Inhalation

5.4. Y-o-Y Growth Trend Analysis By Component, 2017-2021

5.5. Absolute $ Opportunity Analysis By Component, 2022-2032

6. Global COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By End User

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021

6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

6.3.1. Hospitals

6.3.2. Private Clinics

6.3.3. Out-patients

6.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

6.5. Absolute $ Opportunity Analysis By End User, 2022-2032

7. Global COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. Asia Pacific

7.3.5. MEA

7.4. Market Attractiveness Analysis By Region

8. North America COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

8.2.1. By Country

8.2.1.1. US

8.2.1.2. Canada

8.2.2. By Component

8.2.3. By End User

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Component

8.3.3. By End User

8.4. Key Takeaways

9. Latin America COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Component

9.2.3. By End User

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Component

9.3.3. By End User

9.4. Key Takeaways

10. Europe COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. U.K.

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Component

10.2.3. By End User

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Component

10.3.3. By End User

10.4. Key Takeaways

11. Asia Pacific COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

11.2.1. By Country

11.2.1.1. China

11.2.1.2. Japan

11.2.1.3. South Korea

11.2.1.4. Rest of Asia Pacific

11.2.2. By Component

11.2.3. By End User

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Component

11.3.3. By End User

11.4. Key Takeaways

12. MEA COPD Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

12.2.1. By Country

12.2.1.1. GCC Countries

12.2.1.2. South Africa

12.2.1.3. Israel

12.2.1.4. Rest of MEA

12.2.2. By Component

12.2.3. By End User

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Component

12.3.3. By End User

12.4. Key Takeaways

13. Key Countries COPD Therapeutics Market Analysis

13.1. US

13.1.1. Pricing Analysis

13.1.2. Market Share Analysis, 2021

13.1.2.1. By Component

13.1.2.2. By End User

13.2. Canada

13.2.1. Pricing Analysis

13.2.2. Market Share Analysis, 2021

13.2.2.1. By Component

13.2.2.2. By End User

13.3. Brazil

13.3.1. Pricing Analysis

13.3.2. Market Share Analysis, 2021

13.3.2.1. By Component

13.3.2.2. By End User

13.4. Mexico

13.4.1. Pricing Analysis

13.4.2. Market Share Analysis, 2021

13.4.2.1. By Component

13.4.2.2. By End User

13.5. Germany

13.5.1. Pricing Analysis

13.5.2. Market Share Analysis, 2021

13.5.2.1. By Component

13.5.2.2. By End User

13.6. U.K.

13.6.1. Pricing Analysis

13.6.2. Market Share Analysis, 2021

13.6.2.1. By Component

13.6.2.2. By End User

13.7. France

13.7.1. Pricing Analysis

13.7.2. Market Share Analysis, 2021

13.7.2.1. By Component

13.7.2.2. By End User

13.8. Spain

13.8.1. Pricing Analysis

13.8.2. Market Share Analysis, 2021

13.8.2.1. By Component

13.8.2.2. By End User

13.9. Italy

13.9.1. Pricing Analysis

13.9.2. Market Share Analysis, 2021

13.9.2.1. By Component

13.9.2.2. By End User

13.10. China

13.10.1. Pricing Analysis

13.10.2. Market Share Analysis, 2021

13.10.2.1. By Component

13.10.2.2. By End User

13.11. Japan

13.11.1. Pricing Analysis

13.11.2. Market Share Analysis, 2021

13.11.2.1. By Component

13.11.2.2. By End User

13.12. South Korea

13.12.1. Pricing Analysis

13.12.2. Market Share Analysis, 2021

13.12.2.1. By Component

13.12.2.2. By End User

13.13. GCC Countries

13.13.1. Pricing Analysis

13.13.2. Market Share Analysis, 2021

13.13.2.1. By Component

13.13.2.2. By End User

13.14. South Africa

13.14.1. Pricing Analysis

13.14.2. Market Share Analysis, 2021

13.14.2.1. By Component

13.14.2.2. By End User

13.15. Israel

13.15.1. Pricing Analysis

13.15.2. Market Share Analysis, 2021

13.15.2.1. By Component

13.15.2.2. By End User

14. Market Structure Analysis

14.1. Competition Dashboard

14.2. Competition Benchmarking

14.3. Market Share Analysis of Top Players

14.3.1. By Regional

14.3.2. By Component

14.3.3. By End User

15. Competition Analysis

15.1. Competition Deep Dive

15.1.1. Pfizer Inc.

15.1.1.1. Overview

15.1.1.2. Product Portfolio

15.1.1.3. Profitability by Market Segments

15.1.1.4. Sales Footprint

15.1.1.5. Strategy Overview

15.1.1.5.1. Marketing Strategy

15.1.2. GlaxoSmithKline plc

15.1.2.1. Overview

15.1.2.2. Product Portfolio

15.1.2.3. Profitability by Market Segments

15.1.2.4. Sales Footprint

15.1.2.5. Strategy Overview

15.1.2.5.1. Marketing Strategy

15.1.3. Abbott Laboratories

15.1.3.1. Overview

15.1.3.2. Product Portfolio

15.1.3.3. Profitability by Market Segments

15.1.3.4. Sales Footprint

15.1.3.5. Strategy Overview

15.1.3.5.1. Marketing Strategy

15.1.4. Almirall

15.1.4.1. Overview

15.1.4.2. Product Portfolio

15.1.4.3. Profitability by Market Segments

15.1.4.4. Sales Footprint

15.1.4.5. Strategy Overview

15.1.4.5.1. Marketing Strategy

15.1.5. Astellas Pharma

15.1.5.1. Overview

15.1.5.2. Product Portfolio

15.1.5.3. Profitability by Market Segments

15.1.5.4. Sales Footprint

15.1.5.5. Strategy Overview

15.1.5.5.1. Marketing Strategy

15.1.6. AstraZeneca Plc

15.1.6.1. Overview

15.1.6.2. Product Portfolio

15.1.6.3. Profitability by Market Segments

15.1.6.4. Sales Footprint

15.1.6.5. Strategy Overview

15.1.6.5.1. Marketing Strategy

15.1.7. Boehringer Ingelheim Pharmaceuticals, Inc.

15.1.7.1. Overview

15.1.7.2. Product Portfolio

15.1.7.3. Profitability by Market Segments

15.1.7.4. Sales Footprint

15.1.7.5. Strategy Overview

15.1.7.5.1. Marketing Strategy

15.1.8. Mylan N.V.

15.1.8.1. Overview

15.1.8.2. Product Portfolio

15.1.8.3. Profitability by Market Segments

15.1.8.4. Sales Footprint

15.1.8.5. Strategy Overview

15.1.8.5.1. Marketing Strategy

15.1.9. Novartis AG

15.1.9.1. Overview

15.1.9.2. Product Portfolio

15.1.9.3. Profitability by Market Segments

15.1.9.4. Sales Footprint

15.1.9.5. Strategy Overview

15.1.9.5.1. Marketing Strategy

15.1.10. Orion Corporation

15.1.10.1. Overview

15.1.10.2. Product Portfolio

15.1.10.3. Profitability by Market Segments

15.1.10.4. Sales Footprint

15.1.10.5. Strategy Overview

15.1.10.5.1. Marketing Strategy

15.1.11. Sunovion Pharmaceuticals, Inc.

15.1.11.1. Overview

15.1.11.2. Product Portfolio

15.1.11.3. Profitability by Market Segments

15.1.11.4. Sales Footprint

15.1.11.5. Strategy Overview

15.1.11.5.1. Marketing Strategy

15.1.12. Teva Pharmaceutical Industries Ltd

15.1.12.1. Overview

15.1.12.2. Product Portfolio

15.1.12.3. Profitability by Market Segments

15.1.12.4. Sales Footprint

15.1.12.5. Strategy Overview

15.1.12.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

List of Tables

Table 1: Global COPD Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global COPD Therapeutics Market Value (US$ Mn) Forecast by Component, 2017-2032

Table 3: Global COPD Therapeutics Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 4: North America COPD Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 5: North America COPD Therapeutics Market Value (US$ Mn) Forecast by Component, 2017-2032

Table 6: North America COPD Therapeutics Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 7: Latin America COPD Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 8: Latin America COPD Therapeutics Market Value (US$ Mn) Forecast by Component, 2017-2032

Table 9: Latin America COPD Therapeutics Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 10: Europe COPD Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 11: Europe COPD Therapeutics Market Value (US$ Mn) Forecast by Component, 2017-2032

Table 12: Europe COPD Therapeutics Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 13: Asia Pacific COPD Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Asia Pacific COPD Therapeutics Market Value (US$ Mn) Forecast by Component, 2017-2032

Table 15: Asia Pacific COPD Therapeutics Market Value (US$ Mn) Forecast by End User, 2017-2032

Table 16: MEA COPD Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 17: MEA COPD Therapeutics Market Value (US$ Mn) Forecast by Component, 2017-2032

Table 18: MEA COPD Therapeutics Market Value (US$ Mn) Forecast by End User, 2017-2032

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global COPD Therapeutics Market Value (US$ Mn) by Component, 2022-2032

Figure 2: Global COPD Therapeutics Market Value (US$ Mn) by End User, 2022-2032

Figure 3: Global COPD Therapeutics Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global COPD Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 5: Global COPD Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 6: Global COPD Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global COPD Therapeutics Market Value (US$ Mn) Analysis by Component, 2017-2032

Figure 8: Global COPD Therapeutics Market Value Share (%) and BPS Analysis by Component, 2022-2032

Figure 9: Global COPD Therapeutics Market Y-o-Y Growth (%) Projections by Component, 2022-2032

Figure 10: Global COPD Therapeutics Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 11: Global COPD Therapeutics Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 12: Global COPD Therapeutics Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 13: Global COPD Therapeutics Market Attractiveness by Component, 2022-2032

Figure 14: Global COPD Therapeutics Market Attractiveness by End User, 2022-2032

Figure 15: Global COPD Therapeutics Market Attractiveness by Region, 2022-2032

Figure 16: North America COPD Therapeutics Market Value (US$ Mn) by Component, 2022-2032

Figure 17: North America COPD Therapeutics Market Value (US$ Mn) by End User, 2022-2032

Figure 18: North America COPD Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America COPD Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 20: North America COPD Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America COPD Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America COPD Therapeutics Market Value (US$ Mn) Analysis by Component, 2017-2032

Figure 23: North America COPD Therapeutics Market Value Share (%) and BPS Analysis by Component, 2022-2032

Figure 24: North America COPD Therapeutics Market Y-o-Y Growth (%) Projections by Component, 2022-2032

Figure 25: North America COPD Therapeutics Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 26: North America COPD Therapeutics Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 27: North America COPD Therapeutics Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 28: North America COPD Therapeutics Market Attractiveness by Component, 2022-2032

Figure 29: North America COPD Therapeutics Market Attractiveness by End User, 2022-2032

Figure 30: North America COPD Therapeutics Market Attractiveness by Country, 2022-2032

Figure 31: Latin America COPD Therapeutics Market Value (US$ Mn) by Component, 2022-2032

Figure 32: Latin America COPD Therapeutics Market Value (US$ Mn) by End User, 2022-2032

Figure 33: Latin America COPD Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America COPD Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 35: Latin America COPD Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America COPD Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America COPD Therapeutics Market Value (US$ Mn) Analysis by Component, 2017-2032

Figure 38: Latin America COPD Therapeutics Market Value Share (%) and BPS Analysis by Component, 2022-2032

Figure 39: Latin America COPD Therapeutics Market Y-o-Y Growth (%) Projections by Component, 2022-2032

Figure 40: Latin America COPD Therapeutics Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 41: Latin America COPD Therapeutics Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 42: Latin America COPD Therapeutics Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 43: Latin America COPD Therapeutics Market Attractiveness by Component, 2022-2032

Figure 44: Latin America COPD Therapeutics Market Attractiveness by End User, 2022-2032

Figure 45: Latin America COPD Therapeutics Market Attractiveness by Country, 2022-2032

Figure 46: Europe COPD Therapeutics Market Value (US$ Mn) by Component, 2022-2032

Figure 47: Europe COPD Therapeutics Market Value (US$ Mn) by End User, 2022-2032

Figure 48: Europe COPD Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe COPD Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 50: Europe COPD Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe COPD Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe COPD Therapeutics Market Value (US$ Mn) Analysis by Component, 2017-2032

Figure 53: Europe COPD Therapeutics Market Value Share (%) and BPS Analysis by Component, 2022-2032

Figure 54: Europe COPD Therapeutics Market Y-o-Y Growth (%) Projections by Component, 2022-2032

Figure 55: Europe COPD Therapeutics Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 56: Europe COPD Therapeutics Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 57: Europe COPD Therapeutics Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 58: Europe COPD Therapeutics Market Attractiveness by Component, 2022-2032

Figure 59: Europe COPD Therapeutics Market Attractiveness by End User, 2022-2032

Figure 60: Europe COPD Therapeutics Market Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific COPD Therapeutics Market Value (US$ Mn) by Component, 2022-2032

Figure 62: Asia Pacific COPD Therapeutics Market Value (US$ Mn) by End User, 2022-2032

Figure 63: Asia Pacific COPD Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 64: Asia Pacific COPD Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 65: Asia Pacific COPD Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific COPD Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific COPD Therapeutics Market Value (US$ Mn) Analysis by Component, 2017-2032

Figure 68: Asia Pacific COPD Therapeutics Market Value Share (%) and BPS Analysis by Component, 2022-2032

Figure 69: Asia Pacific COPD Therapeutics Market Y-o-Y Growth (%) Projections by Component, 2022-2032

Figure 70: Asia Pacific COPD Therapeutics Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 71: Asia Pacific COPD Therapeutics Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 72: Asia Pacific COPD Therapeutics Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 73: Asia Pacific COPD Therapeutics Market Attractiveness by Component, 2022-2032

Figure 74: Asia Pacific COPD Therapeutics Market Attractiveness by End User, 2022-2032

Figure 75: Asia Pacific COPD Therapeutics Market Attractiveness by Country, 2022-2032

Figure 76: MEA COPD Therapeutics Market Value (US$ Mn) by Component, 2022-2032

Figure 77: MEA COPD Therapeutics Market Value (US$ Mn) by End User, 2022-2032

Figure 78: MEA COPD Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 79: MEA COPD Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 80: MEA COPD Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA COPD Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA COPD Therapeutics Market Value (US$ Mn) Analysis by Component, 2017-2032

Figure 83: MEA COPD Therapeutics Market Value Share (%) and BPS Analysis by Component, 2022-2032

Figure 84: MEA COPD Therapeutics Market Y-o-Y Growth (%) Projections by Component, 2022-2032

Figure 85: MEA COPD Therapeutics Market Value (US$ Mn) Analysis by End User, 2017-2032

Figure 86: MEA COPD Therapeutics Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 87: MEA COPD Therapeutics Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 88: MEA COPD Therapeutics Market Attractiveness by Component, 2022-2032

Figure 89: MEA COPD Therapeutics Market Attractiveness by End User, 2022-2032

Figure 90: MEA COPD Therapeutics Market Attractiveness by Country, 2022-2032

September 2022
REP-GB-4337
342 pages
Healthcare

Book Now

CUSTOMIZE THIS RESEARCH

Which are the positive and negative factors impacting the COPD Therapeutics Market
How can you develop stable and lucrative revenue streams?
What will be your strategy to make top customers shift towards your brand?
Which significant steps can you take to stay ahead of competitors?
Get a complete personalized report with a scorecard of target partners

Customize Now